Ignite Creation Date:
2025-12-25 @ 3:11 AM
Ignite Modification Date:
2025-12-26 @ 1:49 AM
Study NCT ID:
NCT03555305
Status:
COMPLETED
Last Update Posted:
2020-11-24
First Post:
2018-06-01
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
A Study of Insulin Glargine (LY2963016) in Healthy Chinese Participants
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'D000069036', 'term': 'Insulin Glargine'}, {'id': 'C000606659', 'term': 'LY2963016 insulin glargine'}], 'ancestors': [{'id': 'D049528', 'term': 'Insulin, Long-Acting'}, {'id': 'D061385', 'term': 'Insulins'}, {'id': 'D010187', 'term': 'Pancreatic Hormones'}, {'id': 'D036361', 'term': 'Peptide Hormones'}, {'id': 'D006728', 'term': 'Hormones'}, {'id': 'D006730', 'term': 'Hormones, Hormone Substitutes, and Hormone Antagonists'}, {'id': 'D010455', 'term': 'Peptides'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'ClinicalTrials.gov@lilly.com', 'phone': '800-545-5979', 'title': 'Chief Medical Officer', 'organization': 'Eli Lilly and Company'}, 'certainAgreement': {'restrictionType': 'GT60', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': 'Up to 14 Days', 'description': 'All randomized participants who received at least one dose of study drug.', 'eventGroups': [{'id': 'EG000', 'title': '0.5 U/kg Insulin Glargine', 'description': 'Participants received single 0.5 U/kg dose of Insulin glargine administered subcutaneously.', 'otherNumAtRisk': 56, 'deathsNumAtRisk': 56, 'otherNumAffected': 0, 'seriousNumAtRisk': 56, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': '0.5 U/kg Lantus', 'description': 'Participants received single 0.5 U/kg dose of Lantus administered subcutaneously.', 'otherNumAtRisk': 58, 'deathsNumAtRisk': 58, 'otherNumAffected': 0, 'seriousNumAtRisk': 58, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Insulin Glargine and Lantus', 'denoms': [{'units': 'Participants', 'counts': [{'value': '56', 'groupId': 'OG000'}, {'value': '58', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': '0.5 U/kg Insulin Glargine', 'description': 'Participants received single 0.5 U/kg dose of Insulin glargine administered subcutaneously.'}, {'id': 'OG001', 'title': '0.5 U/kg Lantus', 'description': 'Participants received single 0.5 U/kg dose of Lantus administered subcutaneously.'}], 'classes': [{'categories': [{'measurements': [{'value': '124', 'spread': '31', 'groupId': 'OG000'}, {'value': '129', 'spread': '33', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric least squares means', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '0.961', 'ciLowerLimit': '0.886', 'ciUpperLimit': '1.04', 'statisticalMethod': 'Linear mixed-effects model', 'nonInferiorityType': 'EQUIVALENCE', 'nonInferiorityComment': 'Analysis was performed using linear mixed effects model and participant as a random effect, with period, sequence, and treatment as fixed effects. The estimate of the ratio of means of each PK/PD parameters between the 2 treatments and the corresponding 90% confidence interval were calculated. A typical bio-equivalence limit (0.8 to 1.25) was used as equivalence margin.'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': '-0.5 and 0 hours predose; 0.5, 1, 2, 3, 4, 6, 9, 12, 15, 18, 21, and 24 hours postdose', 'description': 'Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Insulin glargine and Lantus.', 'unitOfMeasure': 'picomole per liter (pmol/L)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'All randomized participants who received at least one dose of study drug and had evaluable PK data.'}, {'type': 'PRIMARY', 'title': 'PK: Area Under the Concentration Versus Time Curve From Time Zero to 24 Hours (AUC[0-24]) of Insulin Glargine and Lantus', 'denoms': [{'units': 'Participants', 'counts': [{'value': '56', 'groupId': 'OG000'}, {'value': '58', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': '0.5 U/kg Insulin Glargine', 'description': 'Participants received single 0.5 U/kg dose of Insulin glargine administered subcutaneously.'}, {'id': 'OG001', 'title': '0.5 U/kg Lantus', 'description': 'Participants received single 0.5 U/kg dose of Lantus administered subcutaneously.'}], 'classes': [{'categories': [{'measurements': [{'value': '2170', 'spread': '28', 'groupId': 'OG000'}, {'value': '2310', 'spread': '29', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric least squares means', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '0.943', 'ciLowerLimit': '0.874', 'ciUpperLimit': '1.02', 'statisticalMethod': 'Linear mixed-effects model', 'nonInferiorityType': 'EQUIVALENCE', 'nonInferiorityComment': 'Analysis was performed using linear mixed effects model and participant as a random effect, with period, sequence, and treatment as fixed effects. The estimate of the ratio of means of each PK/PD parameters between the 2 treatments and the corresponding 90% confidence interval were calculated. A typical bio-equivalence limit (0.8 to 1.25) was used as equivalence margin.'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': '-0.5 and 0 hours predose; 0.5, 1, 2, 3, 4, 6, 9, 12, 15, 18, 21, and 24 hours postdose', 'description': 'PK: Area Under the Concentration Versus Time Curve From Time Zero to 24 Hours (AUC\\[0-24\\]) of Insulin glargine and Lantus.', 'unitOfMeasure': 'picomole*hour per liter (pmol*hr/L)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'All randomized participants who received at least one dose of study drug and had evaluable PK data.'}, {'type': 'SECONDARY', 'title': 'Pharmacodynamics (PD): Total Amount of Glucose Infused (Gtot)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '56', 'groupId': 'OG000'}, {'value': '58', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': '0.5 U/kg Insulin Glargine', 'description': 'Participants received single 0.5 U/kg dose of Insulin glargine administered subcutaneously.'}, {'id': 'OG001', 'title': '0.5 U/kg Lantus', 'description': 'Participants received single 0.5 U/kg dose of Lantus administered subcutaneously.'}], 'classes': [{'categories': [{'measurements': [{'value': '2390', 'spread': '43', 'groupId': 'OG000'}, {'value': '2680', 'spread': '40', 'groupId': 'OG001'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': '30 minutes predose through 24 hours postdose', 'description': 'Gtot was the total glucose infusion over the clamp duration and was used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations were held constant after the administration of Insulin glargine or Lantus by adjusting the exogenous glucose infusion rate. Data presented were adjusted by the body weight.', 'unitOfMeasure': 'milligrams/kilogram (mg/kg)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'All randomized participants who received at least one dose of study drug and had evaluable Gtot data.'}, {'type': 'SECONDARY', 'title': 'PD: Maximum Glucose Infusion Rate (Rmax)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '56', 'groupId': 'OG000'}, {'value': '58', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': '0.5 U/kg Insulin Glargine', 'description': 'Participants received single 0.5 U/kg dose of Insulin glargine administered subcutaneously.'}, {'id': 'OG001', 'title': '0.5 U/kg Lantus', 'description': 'Participants received single 0.5 U/kg dose of Lantus administered subcutaneously.'}], 'classes': [{'categories': [{'measurements': [{'value': '2.72', 'spread': '37', 'groupId': 'OG000'}, {'value': '2.99', 'spread': '36', 'groupId': 'OG001'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': '30 minutes predose through 24 hours postdose', 'description': 'Rmax is the maximum infusion rate of glucose administered intravenously needed to maintain target blood glucose level and is used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations are held constant after the administration of Insulin glargine or Lantus by adjusting the exogenous glucose infusion rate. Data presented were adjusted by the body weight.', 'unitOfMeasure': 'milligrams/kilograms/minute (mg/kg/min)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'All randomized participants who received at least one dose of study drug and had evaluable Rmax data.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Sequence 1', 'description': 'Period 1: Participants received 0.5 units per kilogram (U/kg) of Insulin glargine subcutaneously.\n\nPeriod 2: Participants received 0.5 U/Kg of Lantus subcutaneously.'}, {'id': 'FG001', 'title': 'Sequence 2', 'description': 'Period 1: Participants received 0.5 U/Kg of Lantus subcutaneously. Period 2: Participants received 0.5 U/Kg of Insulin glargine subcutaneously.'}], 'periods': [{'title': 'Period 1', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '29'}, {'groupId': 'FG001', 'numSubjects': '29'}]}, {'type': 'Received at Least 1 Dose of Study Drug', 'achievements': [{'groupId': 'FG000', 'numSubjects': '29'}, {'groupId': 'FG001', 'numSubjects': '29'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '29'}, {'groupId': 'FG001', 'numSubjects': '27'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '2'}]}], 'dropWithdraws': [{'type': 'Physician Decision', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}]}, {'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}]}]}, {'title': 'Period 2', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '29'}, {'groupId': 'FG001', 'numSubjects': '27'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '29'}, {'groupId': 'FG001', 'numSubjects': '27'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}]}]}], 'preAssignmentDetails': 'Two period crossover study, with a minimum of 7 days washout period between each period.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '58', 'groupId': 'BG000'}]}], 'groups': [{'id': 'BG000', 'title': 'Overall', 'description': 'Participants received 0.5 U/Kg of Insulin glargine and Lantus subcutaneously as per dosing schedule.'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '24.9', 'spread': '2.4', 'groupId': 'BG000'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '32', 'groupId': 'BG000'}]}, {'title': 'Male', 'measurements': [{'value': '26', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'calculatePct': False, 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '58', 'groupId': 'BG000'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'calculatePct': False, 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Asian', 'measurements': [{'value': '58', 'groupId': 'BG000'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Black or African American', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'White', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'calculatePct': False, 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'China', 'categories': [{'measurements': [{'value': '58', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'calculatePct': False, 'unitOfMeasure': 'Participants'}], 'populationDescription': 'All randomized participants who received at least one dose of study drug.'}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2018-12-18', 'size': 3616790, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2020-06-15T23:04', 'hasProtocol': True}, {'date': '2019-05-06', 'size': 399559, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2020-06-15T23:05', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'BASIC_SCIENCE', 'interventionModel': 'CROSSOVER'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 58}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2018-09-26', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2019-11-15', 'completionDateStruct': {'date': '2019-11-04', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2020-10-30', 'studyFirstSubmitDate': '2018-06-01', 'resultsFirstSubmitDate': '2020-10-30', 'studyFirstSubmitQcDate': '2018-06-01', 'lastUpdatePostDateStruct': {'date': '2020-11-24', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2020-10-30', 'studyFirstPostDateStruct': {'date': '2018-06-13', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2020-11-24', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2019-11-04', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Insulin Glargine and Lantus', 'timeFrame': '-0.5 and 0 hours predose; 0.5, 1, 2, 3, 4, 6, 9, 12, 15, 18, 21, and 24 hours postdose', 'description': 'Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Insulin glargine and Lantus.'}, {'measure': 'PK: Area Under the Concentration Versus Time Curve From Time Zero to 24 Hours (AUC[0-24]) of Insulin Glargine and Lantus', 'timeFrame': '-0.5 and 0 hours predose; 0.5, 1, 2, 3, 4, 6, 9, 12, 15, 18, 21, and 24 hours postdose', 'description': 'PK: Area Under the Concentration Versus Time Curve From Time Zero to 24 Hours (AUC\\[0-24\\]) of Insulin glargine and Lantus.'}], 'secondaryOutcomes': [{'measure': 'Pharmacodynamics (PD): Total Amount of Glucose Infused (Gtot)', 'timeFrame': '30 minutes predose through 24 hours postdose', 'description': 'Gtot was the total glucose infusion over the clamp duration and was used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations were held constant after the administration of Insulin glargine or Lantus by adjusting the exogenous glucose infusion rate. Data presented were adjusted by the body weight.'}, {'measure': 'PD: Maximum Glucose Infusion Rate (Rmax)', 'timeFrame': '30 minutes predose through 24 hours postdose', 'description': 'Rmax is the maximum infusion rate of glucose administered intravenously needed to maintain target blood glucose level and is used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations are held constant after the administration of Insulin glargine or Lantus by adjusting the exogenous glucose infusion rate. Data presented were adjusted by the body weight.'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Healthy']}, 'referencesModule': {'references': [{'pmid': '34410042', 'type': 'DERIVED', 'citation': 'Liu H, Wang F, Ji Y, Ma T, Li H, Linnebjerg H, Chua L, Tham LS, Yu Y. A Euglycemic Glucose Clamp Study to Evaluate the Bioavailability of LY2963016 Relative to Insulin Glargine in Healthy Chinese Subjects. Clin Pharmacol Drug Dev. 2021 Dec;10(12):1452-1459. doi: 10.1002/cpdd.1014. Epub 2021 Aug 19.'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to compare a study drug known as Insulin glargine with Lantus in healthy Chinese participants. Blood samples will be taken to compare how the body handles the drugs and how they affect blood sugar levels. Side effects and tolerability will be documented. The study will last at least 18 days, not including screening. Screening is required within 4 weeks prior to the start of the study.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT'], 'maximumAge': '40 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Are native Chinese men or women. Native Chinese is defined as a participant who has both parents and all 4 grandparents of Chinese origin.\n* For females of childbearing potential (defined as not surgically sterilised and between menarche and 1-year postmenopause) only:\n\n * Negative serum pregnancy test at the time of screening.\n * Are not lactating.\n * Intend not to become pregnant during the study.\n * Are sexually inactive or have practiced a reliable method of birth control for at least 6 weeks prior to screening.\n * Agree to continue to use a reliable method of birth control (as determined by the investigator) during the study.\n* For females not of childbearing potential, must be:\n\n * Surgically sterile, defined as having had a hysterectomy or bilateral oophorectomy or tubal ligation, and/or\n * Menopausal, defined as having had no menses for at least 1 year, or a plasma follicular stimulating hormone value of \\>40 milli-international units per milliliter (mIU/mL) and no menses for at least 6 months, unless the participant is taking hormone-replacement therapy.\n* Having fasting plasma glucose \\<110 milligrams per deciliter (mg/dL) (\\<6.1 millimoles per liter \\[mmol/L\\]) and 2-hour glucose level \\<140 mg/dL (\\<7.8 mmol/L) on the 75 grams (g) oral glucose tolerance test.\n* Have a body mass index (BMI) between 18 and 28 kilograms per meter squared (kg/m²), inclusive, at screening.\n* Are nonsmokers, have not smoked for at least 6 months prior to entering the study, and agree not to smoke (cigars, cigarettes, or pipes) or use smokeless tobacco for the duration of the study.\n* Have normal blood pressure and pulse rate at screening, as determined by the investigator.\n* Have an electrocardiogram (ECG), at screening, considered as within normal limits by the investigator.\n* Have clinical laboratory test results within normal reference range for the population or investigator site, or results with acceptable deviations that are judged to be not clinically significant by the investigator.\n\nExclusion Criteria:\n\n* Have a history of first-degree relatives known to have diabetes mellitus.\n* Have known allergies to insulin glargine or its excipients, or related drugs, or heparin, or have a history of relevant allergic reactions of any origin.\n* Have a significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, haematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data.\n* Show evidence of human immunodeficiency virus infection (HIV) and/or positive human HIV antibodies.\n* Have positive hepatitis B surface antigen.\n* Have donated \\>400 mL of blood in the last 6 months or donated \\>100 mL within the last 30 days.\n* Have an average weekly alcohol intake that exceeds 21 units per week (males) and 14 units per week (females), or are unwilling to stop alcohol consumption while resident in the clinical research unit (CRU) (1 unit = 12 ounces or 360 mL of beer; 5 ounces or 150 mL of wine; 1.5 ounces or 45 mL of distilled spirits).\n* Intend to use: prescription medication or over-the-counter medication or Chinese traditional medicine within 14 days before dosing (apart from vitamin/mineral supplements, occasional paracetamol, thyroid replacement, or birth control methods). If this situation arises, an otherwise suitable participant may be included at the discretion of the investigator.'}, 'identificationModule': {'nctId': 'NCT03555305', 'briefTitle': 'A Study of Insulin Glargine (LY2963016) in Healthy Chinese Participants', 'organization': {'class': 'INDUSTRY', 'fullName': 'Eli Lilly and Company'}, 'officialTitle': 'Relative Bioavailability of LY2963016 to LANTUS® After Single-Dose Subcutaneous Administration in Healthy Chinese Subjects', 'orgStudyIdInfo': {'id': '13877'}, 'secondaryIdInfos': [{'id': 'I4L-MC-ABEF', 'type': 'OTHER', 'domain': 'Eli Lilly and Company'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Insulin Glargine', 'description': 'Participants received 0.5 units per kilogram (U/kg) of Insulin Glargine subcutaneously (SC).', 'interventionNames': ['Drug: Insulin Glargine']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Lantus', 'description': 'Participants received 0.5 U/Kg of Lantus subcutaneously.', 'interventionNames': ['Drug: Lantus']}], 'interventions': [{'name': 'Insulin Glargine', 'type': 'DRUG', 'otherNames': ['LY2963016', 'Basaglar'], 'description': 'Administered SC', 'armGroupLabels': ['Insulin Glargine']}, {'name': 'Lantus', 'type': 'DRUG', 'otherNames': ['Insulin Glargine'], 'description': 'Administered SC', 'armGroupLabels': ['Lantus']}]}, 'contactsLocationsModule': {'locations': [{'zip': '610041', 'city': 'Chengdu', 'state': 'Sichuan', 'country': 'China', 'facility': 'West China Hospital of Sichuan University', 'geoPoint': {'lat': 30.66667, 'lon': 104.06667}}], 'overallOfficials': [{'name': 'Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Eli Lilly and Company'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Eli Lilly and Company', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}